

Overfeeding Polyunsaturated and Saturated Fat Causes Distinct Effects on Liver and Visceral Fat Accumulation in Humans

Running title: Fatty acid overfeeding and ectopic fat

Fredrik Rosqvist,¹ David Iggman,^{1,2} Joel Kullberg,³ Jonathan Cedernaes J,⁴ Hans-Erik Johansson,¹ Anders Larsson,⁵ Lars Johansson,^{3,6} Håkan Ahlström,³ Peter Arner,⁷ Ingrid Dahlman,⁷ Ulf Risérus¹

¹Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Sweden

²Center for Clinical Research Dalarna, Falun, Sweden

³Department of Radiology, Uppsala University, Sweden

⁴Department of Neuroscience, Uppsala University, BMC, Sweden

⁵Department of Medical Sciences, Uppsala University, Sweden

⁶AstraZeneca, R&D, Molndal, Sweden

⁷Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden

Correspondence:

Ulf Risérus, Clinical nutrition and metabolism

Department of public health and caring sciences

Uppsala Science Park, 75185 Uppsala, Sweden

E-mail: ulf.riserus@pubcare.uu.se

Phone: +46186117971

Word count: 4080

Tables: 5

Figures: 3

Excess ectopic fat storage is linked to type 2 diabetes. The importance of dietary fat composition for ectopic fat storage in humans is unknown. We investigated liver fat accumulation and body composition during overfeeding saturated (SFA) or polyunsaturated (PUFA) fat. LIPOGAIN was a double-blind, parallel-group, randomized trial. Thirty-nine young and normal-weight individuals were overfed muffins high in SFA (palm oil) or n-6 PUFA (sunflower oil) for 7 weeks. Liver fat, visceral (VAT), subcutaneous abdominal (SAT), and total adipose tissue (TAT), pancreatic fat, and lean tissue was assessed by MRI. Transcriptomics were performed in SAT. Both groups gained similar weight. SFA however markedly increased liver fat compared with PUFA and caused 2-fold larger increase in VAT than PUFA. Conversely, PUFA caused a nearly 3-fold larger increase in lean tissue than SFA. Increase in liver fat directly correlated with changes in plasma SFA and inversely with PUFA. Genes involved in regulating energy dissipation, insulin resistance, body composition and fat cell differentiation in SAT were differentially regulated between diets, and associated with increased PUFA in SAT. In conclusion, overeating SFA promotes hepatic and visceral fat storage whereas excess energy from PUFA may instead promote lean tissue in healthy humans.

Trial registration: [clinicaltrials.gov Identifier: NCT01427140](https://clinicaltrials.gov/ct2/show/study/NCT01427140)

Fat accumulation in the liver, pancreas and abdomen may have long-term, adverse metabolic consequences (1-3). Although obesity is a major health concern, abdominal obesity is of greater clinical relevance. Accumulation of liver fat, including non-alcoholic fatty liver disease (NAFLD), is present in ~25% of adults in Western countries and has been proposed as a causative factor in the development of cardiometabolic disorders and type 2 diabetes (4-8). In obesity, the prevalence of NAFLD is extremely high and may reach 75% (9). Thus, liver fat may be a key target in the prevention and treatment of metabolic diseases. Why certain individuals deposit liver fat to a larger extent than others during weight gain is unknown. High-fat diets have been shown to increase liver fat in both humans and rodents when compared to low-fat diets (10-12). Cross-sectional data suggest that dietary fat composition could play a key role in liver fat accumulation with polyunsaturated fatty acids (PUFA) inversely (13) and saturated fatty acids (SFA) directly associated with liver fat and liver fat markers (14, 15). In addition, animals fed high-fat diets with PUFA reduced body and liver fat accumulation compared to SFA diets (16-21). In the recent HEPFAT-trial, we showed that an isocaloric diet rich in PUFA given for 10 weeks reduced liver fat content and tended to reduce insulin resistance compared with a diet rich in SFA in individuals with abdominal obesity and type 2 diabetes (22).

Overweight and obesity are mainly results of long-term energy excess. To prevent early excessive adiposity and its metabolic consequences, it is necessary to investigate dietary factors that could initially influence body fat accumulation and ectopic fat storage. We hypothesized that liver fat accumulation during moderate weight gain could be counteracted if the excess energy originate mainly from PUFA rather than from SFA. The aim was to investigate the effects of excess intake of the major n-6 PUFA in the diet, linoleic acid, or the

major SFA in the diet, palmitic acid, on liver fat accumulation, body composition, and adipose tissue gene expression in healthy, normal-weight individuals.

RESEARCH DESIGN AND METHODS

Participants

Healthy, normal weight men and women were recruited by local advertising. Inclusion criteria were age 20 to 38 years, BMI 18 to 27 kg/m², and free from diabetes and liver disease. Exclusion criteria included abnormal clinical chemistry, alcohol or drug abuse, pregnancy, lactation, claustrophobia, intolerance to gluten, egg or milk protein, use of drugs influencing energy metabolism, use of omega-3 supplements, and regular heavy exercise (>3 h/week). Subjects were instructed to maintain their habitual diet and physical activity level throughout the study. Subjects were fasted for 12 hours before measurements and were discouraged from physical exercise or alcohol intake 48 hours before measurements.

Study Design

The LIPOGAIN study was a 7-week, double-blind, randomized, controlled trial with parallel group design in free-living subjects. The study was carried out from August through December 2011 at the Uppsala University Hospital, Uppsala, Sweden. Subjects were randomized by drawing lots, with a fixed block size of 4 and allocation ratio 1:1. Subjects were stratified by sex, and were unaware of the block size. The allocation sequence was only known by one of the researchers (FR) but concealed from all other investigators and participants. Double-blinding was ensured by labeling and the code was concealed from all investigators until the study was finalized.

Dietary Intervention

Forty-one participants were randomized to eat muffins containing either sunflower oil (high in the major dietary PUFA, linoleic acid, 18:2 n-6) or palm oil (high in the major SFA, palmitic acid, 16:0). Body weight was measured and muffins were provided to participants weekly at the clinic. Muffins were baked in large batches under standardized conditions in a metabolic kitchen at Uppsala University. Muffins were added to the habitual diet, and the amount was individually adjusted to achieve a 3% weight gain. The amount of muffins consumed per day was individually adjusted weekly, i.e. altered by +/- 1 muffin/day depending on the rate of weight gain of the individual. Subjects were allowed to eat the muffins anytime during the day. Except for fat quality, the muffins were identical with regard to energy, fat, protein, carbohydrate, and cholesterol content, as well as taste and structure. The composition of the muffins provided 51% of energy from fat, 5% from protein, and 44% from carbohydrates. The sugar to starch ratio was 55:45. We chose palm oil as the source of SFA for several reasons; it is particularly high in palmitic acid and low in linoleic acid, and is widely used in various foods globally. Sunflower oil was chosen as the source of PUFA because it is high in linoleic acid (the major PUFA in Western diet) but low in palmitic acid. Both oils were devoid of cholesterol and n-3 PUFA, thus avoiding potential confounding of these nutrients.

Outcome Measures

The primary outcome of this study was liver fat content (MRI). Secondary outcomes included other body fat depots (MRI and BodPod), total body fat (MRI and BodPod), and lean tissue (MRI and BodPod). All outcome measures were measured at two time-points; at baseline and at the end of the intervention. MRI was the primary assessment method

Assessments of Liver Fat, Pancreatic Fat and Body Composition

Liver fat content, pancreas fat content and body composition were assessed by MRI, using a 1.5T Achieva clinical scanner (Philips Healthcare, Best, Netherlands) modified to allow arbitrary table speed. Collection and analyses of the MRI data were performed by two operators at one center under blinded conditions. The CV:s between the two operators were $2.14 \pm 2.14\%$ and the results from the two operators did not differ significantly ($p > 0.4$). The average from the two operators was used. Body composition was also measured using whole body air displacement plethysmography (BodPod, COSMED®) according to manufacturer's instructions. Pancreas fat content was assessed by duplicate measurements (standard deviation 0.36%) and the average was used. The same images were used as from the liver fat measurements. The operator was trained by an experienced radiologist. Total body water content was measured by bioelectrical impedance analysis (Tanita BC-558, Tanita Corporation, Japan).

Global Transcriptome Analysis of Adipose Tissue

Adipose tissue biopsies were taken subcutaneously, 3 to 4 cm below and lateral to the umbilicus by needle aspiration under local anaesthesia (1% lidocaine). The samples were washed with saline, quickly frozen in dry ice covered with ethanol, and stored at -70°C until analysis. Hybridised biotinylated complementary RNA was prepared from total RNA and hybridized to a GeneChip Human Gene 1.1 ST Array (Affymetrix Inc., Santa Clara, CA, USA) using standardised protocols (Affymetrix Inc.). The microarray data have been submitted to GEO in a MIAME-compliant format (GSE43642).

Assessment of Fat Oxidation

D-3-hydroxybutyrate was analyzed as a marker of hepatic β -oxidation, using a kinetic enzymatic method utilizing Ranbut reagent (RB1008, Randox Laboratories, Crumlin, UK) on

a Mindray BS-380 chemistry analyzer (Shenzhen Mindray Bio-Medical Electronics, Shenzhen, China). All samples were analyzed in a single batch.

Dietary Assessment, Physical Activity, and Compliance

Dietary intake was assessed by 4-day weighed food records (at baseline and week 7), and processed with Dietist XP version 3.1 dietary assessment software. During these 4-day periods, subjects wore accelerometers (Philips Respironics Actical, Andover, MA, USA) on their right ankle to assess physical activity. Food craving, hunger, and satiety were assessed in the morning (only at week 7) by the Food Craving Inventory (FCI) and Visual Analogue Scales (VAS), respectively. Fatty acid composition was measured in the intervention oils as well as in plasma cholesterol esters and adipose tissue triglycerides by gas chromatography as previously described (22, 23). Hepatic stearoyl-CoA desaturase-1 (SCD-1) activity was estimated as the 16:1n-7/16:0 ratio in cholesterol esters (22).

Biochemical Measures

Fasting concentrations of plasma glucose and serum insulin were measured as previously described (22) and HOMA-IR was calculated (24). Plasma total adiponectin concentrations were measured by ELISA (Mercodia, 10-1193-01, Sweden).

Statistical Analysis

Based on previous data (22), 22 subjects per group were needed to detect a 1.5% difference between groups in liver fat with $\alpha=0.05$ and $\beta=0.2$. Differences in changes between groups were analyzed per protocol with Student's t-test. Nonparametric variables were log-transformed, or analysed nonparametrically (e.g. liver fat) with a Wilcoxon test if normality was not attained by the Shapiro-Wilk test and Q-Q-plots. Confidence intervals were, however,

obtained using t-test calculations for all variables. Data is given as mean (SD) or median (interquartile range [IQR]). Correlations between outcome variables and fatty acids are given as Pearson's r or Spearman's ρ . A P-value <0.05 was considered statistically significant. SPSS version 21 and JMP version 10.0.0 were used for analysing data. Significance Analysis of Microarrays (SAM) was used to compare gene expression between groups.

Ethics

This study was conducted in accordance with the Declaration of Helsinki. All subjects gave written informed consent prior to inclusion, and the study was approved by the regional ethical committee.

RESULTS

Of the 55 participants assessed for eligibility, 41 were randomized, but 2 dropped out before the study started, leaving 39 participants with baseline data. All 39 participants completed the study (Figure 1). One individual from each group was excluded from the primary analyses due to considerable and unexplained weight loss during the intervention (>3 SD below the mean weight gain, more than can be attributed to day-to-day variation). Including those 2 outliers, however, did not affect the results, except for differences between groups for the BodPod-analyses, which were no longer statistically significant in the intention-to-treat analysis. Presented data are thus based on 37 participants who were considered compliant with the intervention. The mean age (26.7 [4.6] vs. 27.1 [3.6]) and sex distribution (5:13 vs. 6:13 women: men, respectively) were similar between the PUFA and SFA groups. Fatty acid composition of the intervention oils are shown in Table 1. Baseline characteristics regarding body composition are shown in Table 2.

Weight Gain, Body Composition, and Fat Oxidation

Both groups gained 1.6 kg in weight, however, the MRI assessment showed that the SFA group gained more liver fat, total fat, and visceral fat, but less lean tissue compared with subjects in PUFA group (Table 2). Relative changes are shown in Figure 2. The ratios of lean:fat tissue gained in the PUFA group and SFA groups were approximately 1:1 and 1:4, respectively. Pancreatic fat decreased by 31% ($P=0.008$) in both groups combined, but without significant differences between groups ($p=0.75$, data not shown). D-3-hydroxybutyrate decreased by 0.11 (0.15) mmol/L or -70% and 0.05 (0.09) mmol/L or -45% in the PUFA and SFA groups, respectively, without significant difference between groups ($P=0.14$). When total body water content was taken into account by using a three-compartment model for assessment of fat and lean tissue, the results remained and were even strengthened (data not shown).

Dietary Intake and Physical Activity

Both groups consumed on average 3.1 [0.5] muffins/day, equalling an additional 750 kcal/day. Both groups increased their energy intake comparably, without any differences in macronutrient intake during the study (Table 3). Food craving, hunger, and satiety showed no differences between groups (data not shown). In both groups combined, energy expenditure due to physical activity was 1039.7 ± 112.5 kcal at baseline, and the total energy expenditure at baseline was 2683.9 ± 245.3 kcal, without differences between groups. Physical activity did not change or differ between groups ($P=0.33$) during the intervention (data not shown).

Plasma and Tissue Fatty Acid Composition

Changes in fatty acid composition in plasma as well as adipose tissue reflected dietary intakes, indicating high compliance (Table 4). In addition to the dietary biomarkers, the

estimated SCD-1 activity in plasma cholesterol esters was decreased by PUFA (Table 4). Changes in liver fat and visceral fat, and total adipose tissue (TAT) were directly associated with changes in plasma palmitic acid, whereas liver fat and TAT was inversely associated with linoleic acid. The SCD-1 index was associated with change in liver fat. Changes in lean tissue were inversely associated with changes in palmitic acid and directly with linoleic acid (Figure 3).

Transcriptomics

Comparison of adipose tissue gene expression between groups at baseline revealed no significant differences in gene expression (false discovery rate [FDR] 50%). Absolute differences in gene expression were calculated for each gene in each subject, comparing after with before intervention. These absolute differences in gene expression were compared between intervention groups with SAM. Twelve genes were significantly differently expressed with FDR 25% and 8 with FDR 0% (Table 5). These absolute differences in gene expression were next adjusted for weight gain and compared between PUFA and SFA. Altogether 20 genes were differentially regulated between groups PUFA and SFA according to SAM (FDR 25%) including the 12 genes previously discovered (Table 5). Five genes that were most differently expressed between groups were selected for polymerase chain reaction (PCR)-confirmation; 3 genes were confirmed (carbonic anhydrase 3, CA3; connective tissue growth factor, CTGF; and aldehyde dehydrogenase 1 family member A1, ALDH1A1) and one gene showed a trend of expression in the same direction (phosphodiesterase 8B, PDE8B, 1-sided $P=0.21$). PFKFB1 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1) could not be confirmed.

Changes in mRNA expression among several of the genes selected for PCR-confirmation were associated with changes in target fatty acids in subcutaneous adipose tissue (SAT). CA3

was inversely associated with SCD-1 index ($r=-0.46$, $P=0.004$) and directly associated with linoleic acid ($r=0.45$, $P=0.006$). PDE8B was directly associated with linoleic acid ($r=0.51$, $P=0.002$) and inversely with palmitic acid ($r=-0.35$, $P=0.035$). CTGF was inversely but not significantly associated with linoleic acid ($\rho=-0.32$, $P=0.06$) and directly with palmitic acid ($r=0.34$, $P=0.04$). ALDH1A1 was inversely associated with linoleic acid ($r=-0.39$, $P=0.02$) and directly with SCD-1 index ($r=0.37$, $P=0.03$).

Glucose, Insulin and Adiponectin

Fasting plasma glucose was 4.6 (4.4 to 5.0) mmol/l and 4.5 (4.3 to 4.9) mmol/l in PUFA and SFA groups at baseline, respectively ($P=0.69$), and was virtually unchanged during the intervention; $+0.06\pm 0.3$ mmol/l and -0.06 ± 0.4 mmol/l in PUFA and SFA groups respectively ($P=0.53$ for difference between groups). Fasting serum insulin was 5.8 ± 2.7 mU/l and 5.0 ± 2.0 mU/l in PUFA and SFA group at baseline, respectively ($P=0.33$), and increased to a similar extent in both groups; $+0.92\pm 2.2$ and $+0.94\pm 1.3$ in PUFA and SFA groups respectively ($P=0.97$). HOMA-IR was 1.23 ± 0.63 and 1.04 ± 0.43 in PUFA and SFA groups at baseline, respectively ($P=0.28$), and increased to a similar extent in both groups during the intervention; $+0.22\pm 0.49$ and $+0.18\pm 0.30$ in PUFA and SFA groups respectively ($P=0.79$). Adiponectin was 8.5 (6.1 to 9.6) and 6.4 (5.4 to 9.4) in PUFA and SFA groups at baseline, respectively ($P=0.24$), and increased with 0.92 ± 1.46 and 0.42 ± 0.94 , respectively ($P=0.34$).

DISCUSSION

Despite comparable weight gain after 49 days, this double-blind trial showed that overeating energy from PUFA prevented deposition of liver fat and visceral- and total fat compared with SFA. Excess energy from SFA caused an increase of liver fat compared with PUFA. Further, the inhibitory effect of PUFA on ectopic fat was accompanied by an augmented increase in

lean tissue and less total body fat deposition compared with SFA. Thus, the type of fat in the diet seems to be a novel and important determinant of liver fat accumulation, fat distribution, and body composition during moderate weight gain. We also observed fatty acid-dependent differences in adipose tissue gene expression. The significant decrease in pancreatic fat in both groups during weight gain was an unexpected finding that needs confirmation due to the low amounts of pancreatic fat in this lean population.

Cross-sectional studies have shown that patients with higher SFA and lower PUFA intake have increased liver fat content (13, 15, 25), which is also in accordance with lower PUFA levels in fatty livers (14, 26). A previous isocaloric trial in abdominally obese subjects indicated that the present associations may be causal, since replacing SFA from butter with PUFA from sunflower oil reduced liver fat (20, 22). Thus, together these trials indicate that SFA (high in 16:0) per se might promote hepatic steatosis, both during isocaloric and hypercaloric conditions. These results also support the current nutritional recommendations in general, i.e. to partly replace SFA with PUFA. PUFA, i.e. linoleic acid are found in plant-based foods such as nuts, seeds, and nontropical vegetable oils (27). Increased intake of these foods have in general been associated with cardiometabolic benefits including lowering blood lipids and reduced risk of CVD and type 2 diabetes (27-29). There are however no clear reasons to believe that sunflower oil would be more effective in preventing liver fat accumulation than other PUFA-rich oils and fats.

The mechanisms behind the differential effects on liver fat deposition are unknown, but may involve differences in hepatic lipogenesis and/or fatty acid oxidation and storage (30). In NAFLD patients, increased de novo lipogenesis is a major contributor to liver fat accumulation and steatosis (31, 32). In the current study, a fructose-SFA interaction on liver

fat is possible since the muffins contained significant amounts of fructose (33). Early animal data showed that carbohydrate-induced lipogenesis was inhibited by adding linoleic acid, whereas palmitate had no effect (34), and SFA has enhanced steatosis and increased hepatic lipogenesis compared with PUFA (20, 21). Hepatic activity of the lipogenic enzyme SCD-1 may be elevated in steatosis (26). Also, SCD-1 deficient mice were protected against hepatic lipogenesis, whereas SCD-1 inhibitors markedly reduced hepatic triglyceride accumulation (35). In humans, a strong association between the change in liver fat and the change in hepatic SCD-1 index was reported in weight-stable subjects (22), a finding currently confirmed during hypercaloric conditions.

PUFA is more readily oxidized than SFA (36-38), thereby potentially lowering hepatic exposure to non-esterified fatty acids, a major substrate in triglyceride synthesis. Concentrations of D-3-hydroxybutyrate were, however, if anything lower with PUFA than SFA, thus not supporting a differential effect on hepatic fat oxidation. Animal studies have also indicated that SFA, compared with PUFA, lowers brown tissue adipose activity and thermogenesis (16-19, 39-45).

The increase in lean tissue was nearly three-fold higher during PUFA overeating compared with SFA. Although lean tissue was a secondary outcome, this finding is intriguing since obese persons with reduced lean tissue (“sarcopenic obesity”) are more insulin resistant and at higher risk for physical disability (46, 47). A previous supplementation trial in postmenopausal women reported that a daily dose of 8 g PUFA (safflower oil) increased lean tissue and reduced trunk fat (48). In accordance, rats isocalorically fed with PUFA (high in linoleic acid) gained more lean tissue and less fat compared with a SFA-rich diet, in line with similar studies (16, 17, 49, 50). The mechanism behind these observations remains to be

determined. The differential increase in lean tissue was consistent when assessed by two different methods (MRI and BodPod). This difference was unlikely an artifact due to changes in total body water content since the results were similar in the three-compartment model. Although supported by animal studies, this finding needs to be replicated in additional human studies.

In the present study, n-6 PUFA was investigated, but it is possible that n-3 PUFA have similar effects on body fat accumulation (50-52). The amount of sunflower oil used in the present study (about 40 g per day) corresponds to about three times the customary intake of linoleic acid in the Swedish population. Given that palm oil was used as the SFA source, the wide use of this oil by the food industry may be of concern. In fact, palm oil is one of the most used oils worldwide, suggesting a potential global impact if it promotes adiposity. The health effects of palm oil, however, remain uncertain and should be further investigated. The effects on ectopic fat deposition observed in this study however does not seem to be palm oil-specific, but rather SFA- or palmitate-specific since we previously showed similar results during isocaloric conditions using butter as the source of SFA (22).

Given the different influence on fat deposition, we expected diet-specific influences on adipose gene expression. Overall, differences in SAT adipose gene expression between diets were modest which may relate to similar weight gain and little differences in SAT. Although speculative, down-regulation of ALDH1A1 by PUFA might be relevant as this gene inhibits energy dissipation and promotes fat storage (53). Interestingly, ALDH1A1 deficient mice are protected from diet-induced liver fat accumulation and insulin resistance (53). The observed associations between changes in SAT fatty acids and in mRNA expression support a direct influence of the fatty acids consumed on adipose tissue gene expression. For example,

ALDH1A1 was inversely associated with changes in linoleic acid, but directly associated with the SCD-1 index. As gene expression was measured only in SAT, the gene expression results cannot be directly extrapolated to other depots, such as VAT and liver fat. Firm conclusions about the mechanisms of PUFA-induced changes in liver metabolism can therefore not be drawn from the current study. These findings thus need confirmation in VAT and liver which may not be feasible in humans. However, a recent animal study (54) investigated the effect of overfeeding rats with different types of fat varying in linoleic acid content. Rats fed a diet higher in PUFA (linoleic acid) showed lower liver fat accumulation together with lower hepatic gene expression of several fatty acid transporters (FATP-2, FATP-5, CD36) and lipogenic enzymes (FASN, ACC, SCD-1) compared with rats fed a diet lower in linoleic acid. Hepatic gene expression of ChREBP and SREBP-1c were also lower in rats fed a diet higher in linoleic acid. Accordingly, we observed that the estimated SCD-1 activity in plasma cholesterol esters (reflecting hepatic metabolism) was markedly decreased in the PUFA-group (Table 4), implying that the mechanisms may be at least partly similar, i.e. decreased hepatic lipogenesis.

Some strengths of this study should be mentioned. This study was double-blinded, which rarely is feasible in dietary interventions which include foods rather than supplements or capsules. Our body composition data are strengthened by consistent findings using 2 independent methods (MRI and BodPod). All subjects completed the trial. Both groups in the present study consumed vegetable oils without any cholesterol, thus excluding any confounding effect of dietary cholesterol (55) that is abundant in SFA from animal sources. Assessment of fatty acid composition in plasma lipids and adipose tissue suggested high adherence to the interventions in both groups. Accelerometer monitoring suggested no bias due to differences in physical activity between groups. As we compared 2 common dietary

fatty acids (the major PUFA, linoleic acid, and the major SFA, palmitic acid) in the Western diet, the results of this study could be relevant to many populations.

This study also has several potential limitations. Notably, our results may not apply to obese or insulin resistant individuals who might show a different response to the diets, both with regard to ectopic fat accumulation and glucose metabolism. Also, the current healthy, young and overall lean individuals had very low liver and visceral fat content at baseline. Thus the lack of differences in fasting insulin concentrations were not surprising, i.e. the absolute increase of liver fat during SFA treatment was most likely too small to produce significant metabolic differences between the diets in this healthy study group. It should however be noted that the study was not designed or powered to examine differences in insulin sensitivity, and we did not measure hepatic or whole-body insulin sensitivity directly, which lowered the ability to detect any possible differences between groups. The data thus need confirmation in older individuals with NAFLD or type 2 diabetes, and in other ethnic groups. The short duration of the study may not resemble long-term effects. However, results on liver fat are strongly supported by similar effects reported in weight-stable obese subjects, in which also modest effects on insulin levels and triglycerides were observed (22). The MRI methods used relied on fixed spectrum models and thus did not allow full characterization of all lipid resonances of the liver spectra to detect changes in liver lipid saturation. However, results from plethysmography were consistent with MRI results regarding body fat deposition. Finally, it should be noted that sunflower oil contains more vitamin E than palm oil, and vitamin E supplementation has decreased steatosis (56). However, the present vitamin E levels were most likely too low to have an effect, and there was no correlation between change in liver fat and change in vitamin E intake (data not shown). Furthermore, the effects of PUFA were not exclusive to liver fat.

In conclusion, overeating different types of fat seems to have different anabolic effects in the body. The fate of SFA appears to be ectopic and general fat accumulation, whereas PUFA instead promotes lean tissue in healthy subjects. Given a detrimental role of liver fat and visceral fat in diabetes, the potential of early prevention of ectopic fat and hepatic steatosis by replacing some SFA with PUFA in the diet should be further investigated.

ACKNOWLEDGEMENTS

U.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. F.R., D.I. and U.R. wrote the manuscript. F.R., D.I., J.K., J.C. and H-E.J. collected data. F.R., D.I., J.K., J.C., H-E.J., H.A., A.L., L.J., P.A., I.D. and U.R. reviewed and edited the manuscript and/or contributed with discussion. F.R., D.I., I.D., J.K., A.L. and U.R. performed data analysis. None of the authors have any conflicts of interest to disclose.

This study was funded by the Swedish Research Council (project K2012-55X-22081-01-3). We also thank Swedish Society of Medicine for support. This work was performed within Excellence of Diabetes Research in Sweden (EXODIAB). Dahlman and Arner had grants from NovoNordisk Foundation. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. We thank Siv Tengblad (Uppsala University) for assessing fatty acids and assistance with baking muffins; Martin Johansson (AarhusKarlshamn Sweden) for kindly donating the study oils; Gunilla Arvidsson, Anders Lundberg and Johan Berglund (Uppsala University, Dept of Radiology) for MRI data collection and analysis and Peter Koken (Philips Research Europe) for technical development regarding the MRI method.

REFERENCES

1. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. *Circulation*. 2012;126(10):1301-13. Epub 2012/09/06.
2. Coutinho T, Goel K, Correa de Sa D, Kragelund C, Kanaya AM, Zeller M, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. *J Am Coll Cardiol*. 2011;57(19):1877-86. Epub 2011/05/07.
3. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. *Diabetes care*. 2007;30(11):2916-21. Epub 2007/08/02.
4. Kotronen A, Yki-Jarvinen H, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH, et al. Comparison of the relative contributions of intra-abdominal and liver fat to components of the metabolic syndrome. *Obesity*. 2011;19(1):23-8. Epub 2010/06/12.
5. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. *Proc Natl Acad Sci USA*. 2009;106(36):15430-5. Epub 2009/08/27.
6. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. *Diabetes care*. 2008;31(1):165-9. Epub 2007/10/16.
7. Kim LJ, Nalls MA, Eiriksdottir G, Sigurdsson S, Launer LJ, Koster A, et al. Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. *Obesity*. 2011;19(6):1265-71. Epub 2010/12/25.
8. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *New Engl J Med*. 2010;363(14):1341-50. Epub 2010/10/01.
9. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. *Ann Intern Med*. 2000;132(2):112-7. Epub 2000/01/22.
10. Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. *J Clin Endocrinol Metab*. 2005;90(5):2804-9. Epub 2005/03/03.
11. van Herpen NA, Schrauwen-Hinderling VB, Schaart G, Mensink RP, Schrauwen P. Three weeks on a high-fat diet increases intrahepatic lipid accumulation and decreases metabolic flexibility in healthy overweight men. *J Clin Endocrinol Metab*. 2011;96(4):E691-5. Epub 2011/01/22.
12. de Meijer VE, Le HD, Meisel JA, Akhavan Sharif MR, Pan A, Nose V, et al. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. *Metabolism*. 2010;59(8):1092-105. Epub 2010/01/12.
13. Petersson H, Arnlov J, Zethelius B, Riserus U. Serum fatty acid composition and insulin resistance are independently associated with liver fat markers in elderly men. *Diab Res Clin Pract*. 2010;87(3):379-84. Epub 2009/12/22.
14. Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. *J Hepatol*. 2008;48(2):300-7. Epub 2007/12/19.
15. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, et al. Effects of identical weight loss on body composition and features of insulin resistance in

obese women with high and low liver fat content. *Diabetes*. 2003;52(3):701-7. Epub 2003/02/28.

16. Dulloo AG, Mensi N, Seydoux J, Girardier L. Differential effects of high-fat diets varying in fatty acid composition on the efficiency of lean and fat tissue deposition during weight recovery after low food intake. *Metabolism*. 1995;44(2):273-9. Epub 1995/02/01.

17. Crescenzo R, Bianco F, Falcone I, Tsalouhidou S, Yepuri G, Mougios V, et al. Hepatic mitochondrial energetics during catch-up fat with high-fat diets rich in lard or safflower oil. *Obesity*. 2012;20(9):1763-72. Epub 2011/07/02.

18. Mercer SW, Trayhurn P. Effect of high fat diets on energy balance and thermogenesis in brown adipose tissue of lean and genetically obese ob/ob mice. *J Nutr*. 1987;117(12):2147-53. Epub 1987/12/01.

19. Matsuo T, Takeuchi H, Suzuki H, Suzuki M. Body fat accumulation is greater in rats fed a beef tallow diet than in rats fed a safflower or soybean oil diet. *Asia Pac J Clin Nutr*. 2002;11(4):302-8. Epub 2002/12/24.

20. de Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. *Am J Physiol Gastrointest Liver Physiol*. 2012;303(5):G589-99. Epub 2012/06/16.

21. Shillabeer G, Hornford J, Forden JM, Wong NC, Lau DC. Hepatic and adipose tissue lipogenic enzyme mRNA levels are suppressed by high fat diets in the rat. *J Lipid Res*. 1990;31(4):623-31. Epub 1990/04/01.

22. Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. *Am J Clin Nutr*. 2012;95(5):1003-12. Epub 2012/04/12.

23. Boberg M, Croon LB, Gustafsson IB, Vessby B. Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway. *Clin Sci*. 1985;68(5):581-7. Epub 1985/05/01.

24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28(7):412-9. Epub 1985/07/01.

25. Petit JM, Guiu B, Duvillard L, Jooste V, Brindisi MC, Athias A, et al. Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. *Clin Nutr*. 2012;31(4):520-5. Epub 2012/01/03.

26. Kotronen A, Seppanen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa AL, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. *Diabetes*. 2009;58(1):203-8. Epub 2008/10/28.

27. Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Lee IM, et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013. Epub 2013/11/14.

28. Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. *Prog Lipid Res*. 2009;48(1):44-51. Epub 2008/11/27.

29. Mozaffarian D, Appel LJ, Van Horn L. Components of a cardioprotective diet: new insights. *Circulation*. 2011;123(24):2870-91. Epub 2011/06/22.

30. Jump DB, Tripathy S, Depner CM. Fatty Acid-Regulated Transcription Factors in the Liver. *Ann Rev Nutr*. 2013. Epub 2013/03/27.

31. Sevastianova K, Santos A, Kotronen A, Hakkarainen A, Makkonen J, Silander K, et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. *Am J Clin Nutr.* 2012;96(4):727-34. Epub 2012/09/07.
32. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. *Diabetes Metabolism.* 2003;29(5):478-85. Epub 2003/11/25.
33. Sobrecases H, Le KA, Bortolotti M, Schneiter P, Ith M, Kreis R, et al. Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. *Diabetes Metabolism.* 2010;36(3):244-6. Epub 2010/05/21.
34. Allmann DW, Gibson DM. Fatty Acid Synthesis during early Linoleic Acid Deficiency in the Mouse. *J Lipid Res.* 1965;6:51-62. Epub 1965/01/01.
35. Kurikawa N, Takagi T, Wakimoto S, Uto Y, Terashima H, Kono K, et al. A Novel Inhibitor of Stearoyl-CoA Desaturase-1 Attenuates Hepatic Lipid Accumulation, Liver Injury and Inflammation in Model of Nonalcoholic Steatohepatitis. *Biol Pharm Bull.* 2013;36(2):259-67. Epub 2013/02/02.
36. Piers LS, Walker KZ, Stoney RM, Soares MJ, O'Dea K. The influence of the type of dietary fat on postprandial fat oxidation rates: monounsaturated (olive oil) vs saturated fat (cream). *Int J Obes Relat Metab Disord.* 2002;26(6):814-21.
37. Jans A, Konings E, Goossens GH, Bouwman FG, Moors CC, Boekschoten MV, et al. PUFAs acutely affect triacylglycerol-derived skeletal muscle fatty acid uptake and increase postprandial insulin sensitivity. *Am J Clin Nutr.* 2012;95(4):825-36. Epub 2012/02/18.
38. DeLany JP, Windhauser MM, Champagne CM, Bray GA. Differential oxidation of individual dietary fatty acids in humans. *Am J Clin Nutr.* 2000;72(4):905-11. Epub 2000/09/30.
39. Matsuo T, Komuro M, Suzuki M. Beef tallow diet decreases uncoupling protein content in the brown adipose tissue of rats. *J Nutr Sci Vitaminol.* 1996;42(6):595-601. Epub 1996/12/01.
40. Sadurskis A, Dicker A, Cannon B, Nedergaard J. Polyunsaturated fatty acids recruit brown adipose tissue: increased UCP content and NST capacity. *Am J Physiol.* 1995;269(2 Pt 1):E351-60. Epub 1995/08/01.
41. Nedergaard J, Becker W, Cannon B. Effects of dietary essential fatty acids on active thermogenesis content in rat brown adipose tissue. *J Nutr.* 1983;113(9):1717-24. Epub 1983/09/01.
42. Becker W. Distribution of ¹⁴C after oral administration of [¹⁻¹⁴C]linoleic acid in rats fed different levels of essential fatty acids. *J Nutr.* 1984;114(9):1690-6. Epub 1984/09/01.
43. Shimomura Y, Tamura T, Suzuki M. Less body fat accumulation in rats fed a safflower oil diet than in rats fed a beef tallow diet. *J Nutr.* 1990;120(11):1291-6.
44. Takeuchi H, Matsuo T, Tokuyama K, Suzuki M. Serum triiodothyronine concentration and Na⁺,K⁺-ATPase activity in liver and skeletal muscle are influenced by dietary fat type in rats. *J Nutr.* 1995;125(9):2364-9. Epub 1995/09/01.
45. Takeuchi H, Matsuo T, Tokuyama K, Shimomura Y, Suzuki M. Diet-induced thermogenesis is lower in rats fed a lard diet than in those fed a high oleic acid safflower oil diet, a safflower oil diet or a linseed oil diet. *J Nutr.* 1995;125(4):920-5.
46. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. *Obesity Res.* 2004;12(12):1995-2004. Epub 2005/02/03.
47. Lim S, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). *Diabetes care.* 2010;33(7):1652-4. Epub 2010/05/13.

48. Norris LE, Collene AL, Asp ML, Hsu JC, Liu LF, Richardson JR, et al. Comparison of dietary conjugated linoleic acid with safflower oil on body composition in obese postmenopausal women with type 2 diabetes mellitus. *Am J Clin Nutr.* 2009;90(3):468-76.
49. Su W, Jones PJ. Dietary fatty acid composition influences energy accretion in rats. *J Nutr.* 1993;123(12):2109-14. Epub 1993/12/01.
50. Yepuri G, Marcelino H, Shahkhalili Y, Aprikian O, Mace K, Seydoux J, et al. Dietary modulation of body composition and insulin sensitivity during catch-up growth in rats: effects of oils rich in n-6 or n-3 PUFA. *Br J Nutr.* 2011:1-14. Epub 2011/02/02.
51. Hill JO, Peters JC, Lin D, Yakubu F, Greene H, Swift L. Lipid accumulation and body fat distribution is influenced by type of dietary fat fed to rats. *Int J Obes Relat Metab Disord.* 1993;17(4):223-36. Epub 1993/04/01.
52. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol.* 2012;56(4):944-51. Epub 2011/10/26.
53. Ziouzenkova O, Orasanu G, Sharlach M, Akiyama TE, Berger JP, Viereck J, et al. Retinaldehyde represses adipogenesis and diet-induced obesity. *Nat Med.* 2007;13(6):695-702. Epub 2007/05/29.
54. Ronis MJ, Baumgardner JN, Marecki JC, Hennings L, Wu X, Shankar K, et al. Dietary fat source alters hepatic gene expression profile and determines the type of liver pathology in rats overfed via total enteral nutrition. *Physiol Genomics.* 2012;44(22):1073-89. Epub 2012/09/20.
55. Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. *Hepatology (Baltimore, Md).* 2013;57(1):81-92. Epub 2012/04/18.
56. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *New Engl J Med.* 2010;362(18):1675-85. Epub 2010/04/30.

Table 1. Fatty Acid Composition of the Intervention Oils

	Sunflower oil	Palm oil
8:0	0.02	0.02
10:0	0.02	0.04
12:0	0.05	0.31
14:0	0.08	1.1
16:0	6.2	47.5
16:1	0.08	0.16
18:0	4.1	4.2
18:1	23.8	37.2
18:2 n-6	65.3	8.9
18:3 n-3	0.08	0.23
20:0	0.26	0.32
20:3 n-6	-	-
20:4 n-6	-	-
20:5 n-3	-	-
22:6 n-3	-	-
Total SFA	10.7	53.5
Total MUFA	23.9	37.4
Total PUFA	65.4	9.2

Abbreviations: SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.

Fatty acids are reported as a percentage of all fatty acids assessed by gas chromatography.

Table 2. Liver Fat and Body Composition Before and After 7 Weeks of SFA or PUFA Overeating*

	PUFA (n=18)		SFA (n=19)		Mean Difference in Change (95% CI)	P-Value
	Baseline	Mean Absolute Change	Baseline	Mean Absolute Change		
Body Weight, kg	67.4 ± 8.2	1.6 ± 0.85	63.3 ± 6.8	1.6 ± 0.96	-0.02 (-0.63 to 0.58)	0.94
BMI, kg/m ²	20.8 (19.5 to 23.1)	0.5 ± 0.3	19.9 (18.9 to 20.7)	0.5 ± 0.3	0.01 (-0.18 to 0.20)	0.98
Waist Girth, cm	79.4 ± 5.6	0.97 ± 2.2	76.1 ± 5.1	1.0 ± 2.3	-0.03 (-1.53 to 1.47)	0.97
Liver Fat, % (MRI)	0.75 (0.65 to 1.0)	0.04 ± 0.24	0.96 (0.79 to 1.1)	0.56 ± 1.0	-0.52 (-1.0 to -0.01)	0.033
Lean Tissue, L (MRI)	43.4 ± 8.4	0.86 ± 0.62	41.8 ± 6.9	0.31 ± 0.68	0.55 (0.11 to 0.98)	0.015
VAT, L (MRI)	0.99 (0.50 to 1.6)	0.11 ± 0.21	0.81 (0.52 to 1.0)	0.22 ± 0.16	-0.12 (-0.24 to 0.01)	0.035
VAT:SAT ratio (MRI)†	0.08 ± 0.04	0.00 ± 0.01	0.07 ± 0.03	0.01 ± 0.01	-0.01 (-0.02 to 0.00)	0.073
Abdominal SAT, L (MRI)	2.2 (1.9 to 3.1)	0.25 ± 0.32	1.8 (1.5 to 2.8)	0.34 ± 0.23	-0.09 (-0.27 to 0.10)	0.32
Total Body Fat, L (MRI)	14.4 (12.6 to 19.6)	0.97 ± 1.0	12.9 (10.4 to 18.2)	1.5 ± 0.70	-0.57 (-1.2 to 0.01)	0.013
Lean Tissue, % (BodPod)	81.9 ± 6.3	-0.81 ± 1.2	85.6 ± 7.4	-1.7 ± 1.1	0.93 (0.15 to 1.70)	0.021

Total Body Fat, % (BodPod)	18.1 ± 6.3	0.81 ± 1.2	14.4 ± 7.4	1.7 ± 1.1	-0.93 (-1.70 to -0.15)	0.021
----------------------------	------------	------------	------------	-----------	------------------------	-------

* Data are means (SD) or median (IQR) and 95% CI. For non-normal variables P-values are obtained from non-parametric analyses. Mean difference in change is calculated as mean absolute change in PUFA minus mean absolute change in SFA.

† Calculated as visceral adipose tissue/(total adipose tissue-visceral adipose tissue).

Abbreviations: CI, confidence interval; IQR, interquartile range; MRI, magnetic resonance imaging; PUFA, polyunsaturated fatty acids; SAT, subcutaneous adipose tissue; SFA, saturated fatty acids; VAT, visceral adipose tissue.

Table 3. Dietary Intake Data Before and After 7 Weeks of Overeating SFA or PUFA*

	PUFA (n=18)		SFA (n=19)		Mean Difference in Change (95% CI)	P-Value
	Baseline	Mean Absolute Change	Baseline	Mean Absolute Change		
Dietary Intake						
Energy, kcal	2504 ± 525	632 ± 499.5	2535.1 ± 591	500 ± 550	132.2 (-218.3 to 482.6)	0.45
Carbohydrates, E%	44.7 ± 8.9	-1.4 ± 6.3	50.2 ± 8.8	-2.5 ± 5.2	1.1 (-2.8 to 4.9)	0.57
Protein, E%	14 (13 to 16)	-2.2 ± 4	14 (14 to 17)	-2.5 ± 2.8	0.3 (-2.1 to 2.6)	0.83
Fat, E%	35.3 ± 5.1	5 ± 5.8	31.7 ± 6.9	5.1 ± 5.6	-0.1 (-3.9 to 3.8)	0.98
SFA, E%	13.1 ± 2.6	-1.6 ± 2.8	11.5 ± 3.6	4.9 ± 2.8	-6.5 (-8.3 to -4.6)	0.0001
MUFA, E %	11.5 ± 2.5	0.9 ± 2.7	9.9 ± 2.8	3 ± 2.7	-2.1 (-3.9 to -0.3)	0.026
PUFA, E%	5 ± 1.5	7.9 ± 2.1	4.2 ± 1.4	0.3 ± 1.3	7.6 (6.4 to 8.8)	0.0001
Alcohol, E%	2 (0 to 8.5)	-1.5 ± 5.5	1 (0 to 3)	-0.2 ± 2.3	-1.3 (-4.2 to 1.6)	0.37

*Data are means (SD) or median (IQR) and 95% CI. For non-normal variables P-values are obtained from non-parametric analyses. Mean difference in change is calculated as mean absolute change in PUFA minus mean absolute change in SFA.

Abbreviations: CI, confidence interval; E%, energy percent; IQR, interquartile range; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids

Table 4. Fatty Acid Composition in Cholesterol Esters (CE) and Subcutaneous Adipose Tissue (SAT) Before and After 7 Weeks of Overeating PUFA or SFA*

	PUFA (n=18)		SFA (n=19)		Mean Difference in Change (95% CI)	P-Value
	Baseline	Mean Change	Baseline	Mean Change		
<i>CE</i>						
14:0	0.61 ± 0.18	-0.04 ± 0.16	0.62 ± 0.13	-0.07 ± 0.09	0.03 (-0.06 to 0.12)	0.5
15:0	0.28 ± 0.06	-0.03 ± 0.04	0.31 ± 0.07	-0.06 ± 0.05	0.03 (-0.004 to 0.06)	0.09
16:0	10.6 ± 0.55	-0.92 ± 0.58	10.6 ± 0.57	0.3 ± 0.59	-1.2 (-1.61 to -0.83)	0.0001
16:1	1.9 ± 0.45	-0.52 ± 0.36	2.0 ± 0.62	0.03 ± 0.46	-0.55 (-0.83 to -0.27)	0.0003
18:0	0.84 ± 0.17	-0.11 ± 0.12	0.74 ± 0.13	-0.06 ± 0.12	-0.05 (-0.13 to 0.03)	0.19
18:1	21.8 ± 1.96	-3.9 ± 1.12	21.6 ± 1.83	-0.02 ± 1.23	-3.9 (-4.7 to -3.13)	0.0001
18:2 n-6	52.5 (51.63 to 55.08)	6.4 ± 2.12	53.3 (51.32 to 55.66)	0.59 ± 2.29	5.8 (4.34 to 7.29)	0.0001
18:3 n-6	0.73 ± 0.28	0.06 ± 0.25	0.71 ± 0.26	0.07 ± 0.28	-0.009 (-0.19 to 0.17)	0.92
18:3 n-3	0.84 ± 0.19	-0.2 ± 0.14	0.97 ± 0.2	-0.12 ± 0.17	-0.07 (-0.17 to 0.03)	0.17
20:3 n-6	0.59 ± 0.11	0.03 ± 0.08	0.66 ± 0.17	0.02 ± 0.12	0.007 (-0.06 to 0.07)	0.84

20:4 n-6	6.3 ± 1.06	-0.02 ± 0.75	6.01 ± 1.38	-0.67 ± 0.6	0.64 (0.19 to 1.1)	0.007
20:5 n-3	1.3 ± 0.54	-0.56 ± 0.56	1.1 ± 0.44	0.03 ± 0.6	-0.6 (-0.98 to -0.21)	0.004
22:6 n-3	0.74 ± 0.21	-0.16 ± 0.13	0.74 ± 0.19	-0.05 ± 0.2	-0.11 (-0.22 to 0.008)	0.07
SCD-1	0.18 ± 0.04	-0.04 ± 0.03	0.19 ± 0.06	-0.002 ± 0.04	-0.03 (-0.06 to -0.009)	0.008
<hr/> SAT						
14:0	4.0 ± 0.70	-0.3 ± 0.37	4.0 ± 0.78	-0.16 ± 0.23	-0.14 (-0.35 to 0.07)	0.18
15:0	0.35 ± 0.08	-0.02 ± 0.02	0.35 ± 0.07	-0.02 ± 0.02	-0.006 (-0.02 to 0.008)	0.42
16:0	21.7 ± 1.55	-1.1 ± 0.66	21.7 ± 1.66	1.2 ± 1.18	-2.3 (-2.9 to -1.6)	0.0001
16:1	4.3 ± 1.05	-0.02 ± 0.41	4.4 ± 0.58	0.46 ± 0.52	-0.49 (-0.81 to -0.17)	0.004
17:0	0.32 ± 0.08	-0.03 ± 0.05	0.31 ± 0.05	-0.03 ± 0.02	0 (0.03 to -0.03)	1.0
18:0	5.0 ± 0.96	-0.35 ± 0.49	4.9 ± 0.81	-0.44 ± 0.5	0.1 (-0.24 to 0.43)	0.56
18:1	50.2 ± 2.41	-0.63 ± 0.83	50.4 ± 2.14	-0.88 ± 1.0	0.26 (-0.34 to 0.88)	0.41
18:2 n-6	11.6 (11.15 to 13.14)	2.4 ± 1.05	11.2 (10.15 to 12.78)	-0.11 ± 0.28	2.5 (1.97 to 3.04)	0.0001
18:3 n-6	0.1 (0.09 to 0.11)	0.009 ± 0.05	0.1 (0.09 to 0.16)	0.004 ± 0.03	0.006 (-0.02 to 0.03)	0.69
18:3 n-3	1.1 ± 0.18	0.02 ± 0.08	1.2 ± 0.21	0.008 ± 0.09	0.009 (-0.05 to 0.06)	0.75
20:3 n-6	0.13 ± 0.02	0.002 ± 0.009	0.13 ± 0.04	-0.005 ± 0.009	0.007 (0.001 to 0.01)	0.018

20:4 n-6	0.26 ± 0.06	0.01 ± 0.02	0.24 ± 0.07	0.009 ± 0.03	0.0006 (-0.02 to 0.02)	0.95
20:5 n-3	0.14 ± 0.04	-0.007 ± 0.02	0.12 ± 0.03	0.0006 ± 0.02	-0.007 (-0.02 to 0.006)	0.27
22:5 n-3	0.17 ± 0.04	-0.008 ± 0.01	0.16 ± 0.04	-0.01 ± 0.02	0.004 (-0.006 to 0.02)	0.41
22:6 n-3	0.15 ± 0.07	-0.01 ± 0.02	0.16 ± 0.07	-0.004 ± 0.03	-0.007 (-0.03 to 0.01)	0.41
SCD-1	0.2 ± 0.05	0.009 ± 0.02	0.2 ± 0.03	0.009 ± 0.03	0.0005 (-0.02 to 0.02)	0.96

*Data are means±SD or median (IQR) and 95% CI. For non-normal variables P-values are obtained from non-parametric analyses.

Abbreviations: SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; SCD-1, stearyl-CoA desaturase-1. Fatty acids are reported as a percentage of all fatty acids assessed by gas chromatography.

Table 5. Comparison of Absolute Gene Expression Difference Before and After 7 Weeks of Overeating SFA or PUFA

Gene name	Symbol	PUFA	SFA	Note
		Change	Change	
carbonic anhydrase III, muscle specific	CA3	1.55	1.02	a,b,c
alpha-kinase 3	ALPK3	1.20	0.86	a,b,c
insulin-like growth factor 1	IGF1	1.22	0.99	a,b,c
phosphodiesterase 8B	PDE8B	1.39	1.02	a,b,c
storkhead box 1	STOX1	1.22	0.89	a,b,c
MOCO sulphurase C-terminal domain containing 1	MOSC1	1.17	1.00	a,b,c
heat shock 70kDa protein 12A	HSPA12A	1.52	1.17	a,b,c
glycerophosphodiester phosphodiesterase domain containing 5	GDPD5	1.37	0.94	a,b,c
odz, odd Oz/ten-m homolog 4	ODZ4	1.80	1.16	a,c
pleckstrin homology domain containing, family H member 2	PLEKHH2	0.82	1.04	a,c
chloride intracellular channel 1	CLIC1	0.87	1.03	a,c
connective tissue growth factor	CTGF	0.81	1.15	a,c
transmembrane protein 120B	TMEM120B	1.46	1.12	c

KIAA0427	KIAA0427	1.34	1.09	c
quinoid dihydropteridine reductase	QDPR	1.25	1.05	c
aldehyde dehydrogenase 9 family, member A1	ALDH9A1	1.32	1.08	c
transmembrane protein 120A	TMEM120A	1.10	0.94	c
FAT tumor suppressor homolog 1	FAT1	1.27	1.08	c
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1	PFKFB1	1.21	1.00	c
aldehyde dehydrogenase 1 family, member A1	ALDH1A1	0.80	1.09	c

Absolute expression difference after vs before intervention groups is significant with (a) FDR 25%, (b) FDR 0%.

Absolute expression differences after vs before intervention was adjusted for differences in weight gain between individuals, followed by comparison between intervention groups at significance FDR 25% (c). For genes significant in this group only, weight-change adjusted differences in expression levels after vs before intervention are shown.

Abbreviations: PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids

FIGURE LEGENDS

Figure 1: Flow Diagram for the LIPOGAIN Trial

Figure 2: Relative Changes in Liver Fat and Body Composition by MRI during 7 Weeks of Overeating SFA or PUFA*

Panels A, B, C, D, E, F.

* Relative changes are calculated for each individual as change during the intervention/baseline measurement. Boxes represent medians and interquartile ranges (IQR), whiskers represent the most extreme value besides outliers, circles represent outliers (>1.5 IQRs outside IQR). P-values represent between group t-test or Wilcoxon test for change week 7-week 0.

Panel A: Change in liver fat is in percentages.

Panels B, C, E and F: Changes are in liters.

Panel D: Visceral: subcutaneous adipose tissue ratio is calculated as visceral adipose tissue/(total adipose tissue-visceral adipose tissue).

Abbreviations: MRI, magnetic resonance imaging; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids

Figure 3: Correlations between Changes in Outcome Measures and Changes in Plasma

Cholesterol Esters*. White circles = PUFA group, black squares = SFA group

Panels A, B, C, D, E, F, G, H, I.

* rho; Spearman's correlation coefficient, r: Pearson's correlation coefficient


Panels A, D, F, and H: 18:2n-6 is linoleic acid (in percentage of all fatty acids by gas chromatography).


Panel B: Stearoyl-CoA desaturase (SCD)-1 index is calculated as palmitoleic/palmitic acid (in percentages of all fatty acids by gas chromatography).

Panel C: The dependent variable (Change in Visceral Adipose Tissue) was log transformed before analysis of Pearson r.

Panels C, E, G, and I: 16:0 is palmitic acid (in percentage of all fatty acids by gas chromatography).

Abbreviations: PUFA, polyunsaturated fatty acid group (represented by circles); SFA, saturated fatty acid group (represented by filled squares).





259x387mm (300 x 300 DPI)

